22 June 2020

New research: multiple low dose therapy

Elize Brolsma

Combining low doses of several cancer drugs at the same time might overcome the important problem of resistance, researchers from the Netherlands Cancer Institute conclude. The lab of Oncode Investigator Rene Bernards shows promising results for this multiple low dose approach. Their paper is published in the scientific journal Nature Communications on June 22nd.

Resistance is a major problem in the treatment of cancer patients. Drugs targeting specific signaling proteins within cancer cells can work very well initially. In the end though, the tumor becomes resistant and starts growing again. That’s why scientists and clinicians focus their attention on outsmarting cancer by combining different drugs. A cocktail of drugs that block several parts of the same signal route in cancer cells, for example, has proven effective, but patients can experience severe side effects.

Nothing plus nothing
Researchers of the Netherlands Cancer Institute think they might have found a way around this problem: multiple low dose therapy. Combining four carefully selected drugs at very low doses appears to block cancer signals very well in the lab, without significant side effects.

Oncode Investigator Rene Bernards says: “I already had ideas on the theory of multiple low dose therapy since 2015. However, my grant proposals on this topic were rejected since the theory was so far from the existing clinical practice. And that’s why Oncode Institute has such an important value to the innovation of science. Thanks to my Oncode base fund, which can be applied freely to novel ideas that might not be funded by others, I was able to push this research forward. And I’m very pleased with the results so far!”

Researcher and first author of the publication João Neto says: “Initially, we didn’t think it was going to work so well. Each drug individually has no effect at all when used in such a low dose. So: nothing plus nothing would be… nothing, right? But we saw a huge synergy when we combined the four drugs at low concentration!”

Four drugs
The researchers treated both lung cancer cells and mice with lung cancer with four medicines: EGFR, RAF, MEK and ERK inhibitors. They’re all blocking proteins that are part of the same communication route within the cell. And the cells of certain lung cancers are addicted to it. They have a mutation in the EGFR gene, making this signal route hyperactive and cell division go through the roof. Patients initially respond well to drugs against EGFR, but once resistant cells find their way around the blockage there aren’t a lot of treatment options left.

Blocking crossroads
Hence the idea of outsmarting the cancer cells by blocking several crossroads instead of one.

João and his colleagues found out they could block the signaling route completely with as little as one fifth of the individual effective drug dose. The cells stopped dividing and died. No resistance. “In mice the tumors also shrank”, he says. “They didn’t disappear completely, like the cells in the lab, because the mice degraded some of the drugs very fast. So, one of the challenges when testing this in human patients will be to sustain the right level of drug in their bodies.”

Multiple low dose treatment
Testing in patients will be the next step. Researchers and clinicians at the Netherlands Cancer Institute still have quite some work to do though, such as translating the current findings in cells and mice to the exact right doses in humans, securing the drugs to be used in the trial, and convince funders to support this important step into the clinic.

“The potential of multiple low dose treatment goes beyond lung cancer”, says João. “We tested cells of several other cancer types and saw the same promising results. In theory it can be applied to a broad range of tumors, as long as they are addicted to a communication pathway within their cells.”

(Press release via the Netherlands Cancer Institute)

Other News

Kops website
New biosensor measures activity of control enzyme MPS1
Researchers from the group of Oncode Investigator Geert Kops (Hubrecht Institute) have developed a biosensor that can precisely depict the activity of the MPS1 enzyme in living cells. MPS1 is responsible for accurate distribution of DNA during cell division; errors in this process can lead to cancer. Using the new biosensor, the researchers discovered that the MPS1 enzyme is significantly less active in colorectal cancer cells. The results were published in the scientific journal Current Biology on the 3rd of September.
Pre-existing immune-resistant cancer cells identified in melanoma
Researchers at the Netherlands Cancer Institute, led by Oncode Investigator Daniel Peeper with Julia Boshuizen as first author, have discovered a cluster of tumor cells that are refractory to immunotherapy and that exists even prior to treatment. This finding, which was published in the scientific journal Nature Communications, may lead to new therapies that eliminate cancer more effectively.


Elize is part of Oncode’s communication team. She has over 10 years of experience in the com-munication industry, both for commercial and non-profit organisations. After obtaining her bache-lor and master degree in communication at Utrecht University, Elize worked as a communication professional at a research institute, PR agency, law firm and internet company. She has a strong focus on external communications and Public Relations. At Oncode - together with her colleagues - Elize produces the monthly newsletters for Oncode Investigators & Researchers and the Oncode digital magazine. She publishes content for the Oncode website and is responsible for all social media channels. She enjoys discussing science with researchers and support them in their outreach.
11 impact value 1
Convey impact, get funding
In order to give our community hands-on advice on how to improve their grant writing, we hosted a 90- minute interactive webinar: Get Funding: Convey the impact of your science.